VRXA
Veraxa Biotech Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$1.76
+15.03%Jul 13, 2026, 11:00 UTC
VERAXA Biotech announced a collaboration with Ardigen to support its BiTAC pipeline of T cell engagers and antibody drug conjugates.
Source:Jun 15, 2026, 00:00 UTC
Xlife Sciences AG disclosed a 16.3% stake in Veraxa Biotech Holding AG via a 13D/G filing.
Jun 10, 2026, 20:15 UTC
VERAXA Biotech completed a business combination with Voyager Acquisition Corp. and will begin trading on NASDAQ under ticker VRXA on June 11, 2026.
Source:May 29, 2026, 00:00 UTC
Voyager Acquisition Corp. issued $27.5 million aggregate principal amount of Senior Secured Notes due August 27, 2027, with monthly partial redemption payments of $2.75 million, secured by a first-priority lien on assets, for working capital and general corporate purposes.